HomeCompareXBIOW vs EPRT

XBIOW vs EPRT: Dividend Comparison 2026

XBIOW yields 11.40% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $21.9K in total portfolio value· pulled ahead in Year 7
10 years
XBIOW
XBIOW
● Live price
11.40%
Share price
$17.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.5K
Annual income
$2,326.31
Full XBIOW calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — XBIOW vs EPRT

📍 EPRT pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXBIOWEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XBIOW + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XBIOW pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XBIOW
Annual income on $10K today (after 15% tax)
$969.21/yr
After 10yr DRIP, annual income (after tax)
$1,977.36/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $9,217.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XBIOW + EPRT for your $10,000?

XBIOW: 50%EPRT: 50%
100% EPRT50/50100% XBIOW
Portfolio after 10yr
$53.4K
Annual income
$7,748.59/yr
Blended yield
14.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

XBIOW
No analyst data
Altman Z
-29.7
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XBIOW buys
0
EPRT buys
0
PoliticianChamberTickerTypeAmountDate
Daniel Goldman🏢 House$EPRT▼ Sell$15,001 - $50,0002023-07-12
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXBIOWEPRT
Forward yield11.40%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$42.5K$64.3K
Annual income after 10y$2,326.31$13,170.85
Total dividends collected$17.2K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: XBIOW vs EPRT ($10,000, DRIP)

YearXBIOW PortfolioXBIOW Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,840$1,140.25$11,212$512.01+$628.00XBIOW
2$13,931$1,261.76$12,689$692.09+$1.2KXBIOW
3$16,293$1,387.43$14,521$944.30+$1.8KXBIOW
4$18,951$1,516.57$16,841$1,302.88+$2.1KXBIOW
5$21,926$1,648.49$19,841$1,821.64+$2.1KXBIOW
6$25,243$1,782.51$23,818$2,587.47+$1.4KXBIOW
7← crossover$28,928$1,917.94$29,230$3,744.65$302.00EPRT
8$33,007$2,054.14$36,816$5,540.38$3.8KEPRT
9$37,508$2,190.46$47,806$8,413.17$10.3KEPRT
10$42,460$2,326.31$64,324$13,170.85$21.9KEPRT

XBIOW vs EPRT: Complete Analysis 2026

XBIOWStock

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Full XBIOW Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this XBIOW vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XBIOW vs SCHDXBIOW vs JEPIXBIOW vs OXBIOW vs KOXBIOW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.